Correlation between PAFAH1B3 Expression Level and Risk of Disease Progression After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients.
10.19746/j.cnki.issn.1009-2137.2023.02.020
- Author:
Zhe-Yun GU
1
,
2
;
Jian TAO
1
,
3
;
Yi-Feng CAI
4
;
Ling WANG
1
,
2
Author Information
1. Department of Hematology, The Second Affiliated Hospital of Nantong University
2. Nantong 226000, Jiangsu Province, China.
3. Nantong 226000, Jiangsu Province, China.E-mail: 18921601068@189.cn.
4. Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
platelet-activating factor acetylhydrolase 1B3;
prognosis;
progression-free survival
- MeSH:
Humans;
Disease Progression;
Hematopoietic Stem Cell Transplantation;
Multiple Myeloma/drug therapy*;
Prognosis;
Retrospective Studies;
Transplantation, Autologous;
1-Alkyl-2-acetylglycerophosphocholine Esterase/genetics*
- From:
Journal of Experimental Hematology
2023;31(2):448-454
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the association between the expression level of platelet-activating factor acetylhydrolase 1B3 (PAFAH1B3 ) gene in bone marrow CD138+ cells of patients with multiple myeloma (MM) treated with autologous hematopoietic stem cell transplantation (AHSCT) and the prognosis within 2 years.
METHODS:147 MM patients treated with AHSCT in The First and The Second Affiliated Hospital of Nantong University from May 2014 to May 2019 were included in the study. Expression level of PAFAH1B3 mRNA in bone marrow CD138+ cells of the patients was detected. Patients with disease progression or death during 2 years of follow-up were included in progression group, and the rest were included in good prognosis group. After comparing the clinical data and PAFAH1B3 mRNA expression levels of the two groups, the patients were divided into high PAFAH1B3 expression group and low PAFAH1B3 expression group based on the median PAFAH1B3 mRNA expression level of the enrolled patients. Progression-free survival rate (PFSR) between the two groups was compared by the Kaplan-Meier method. The related factors of prognosis within 2 years were analyzed by univariate analysis and multivariate COX regression analysis.
RESULTS:At the end of follow-up, there were 13 patients lost to follow-up. Finally, 44 patients were included in the progression group and 90 patients were included in the good prognosis group. Age in the progression group was higher than that in the good prognosis group, the proportion of patients with CR+VGPR after transplantation in the progression group was lower than that in the good prognosis group, and there was a statistical difference between two groups in the cases distribution of ISS stage (all P<0.05). PAFAH1B3 mRNA expression level and the proportion of patients with LDH>250U/L in the progression group were higher than those in the good prognosis group, and platelet count in the progression group was lower than that in the good prognosis group (all P<0.05). Compared with the low PAFAH1B3 expression group, the 2-year PFSR of the high PAFAH1B3 expression group was significantly lower (log-rank χ2=8.167, P=0.004). LDH>250U/L (HR=3.389, P=0.010), PAFAH1B3 mRNA expression (HR=50.561, P=0.001) and ISS stage Ⅲ(HR=1.000, P=0.003) were independent risk factors for prognosis in MM patients, and ISS stage Ⅰ (HR=0.133, P=0.001) was independent protective factor.
CONCLUSION:The expression level of PAFAH1B3 mRNA in bone marrow CD138+ cells is related to the prognosis of MM patients treated with AHSCT, and detecting PAFAH1B3 mRNA expression can bring some information for predicting PFSR and prognostic stratification of patients.
